公开(公告)号：US11045448B2

公开(公告)日：2021-06-29

申请号：US16497856

申请日：2018-03-30

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Shilin Xu ,  Liyue Huang ,  Jeanne Stuckey ,  Tianfeng Xu

IPC: A61K31/397 ,  A61K31/4523 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/5377 ,  C07D205/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14

Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US20200022953A1

公开(公告)日：2020-01-23

申请号：US16497856

申请日：2018-03-30

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Shilin Xu ,  Liyue Huang ,  Jeanne Stuckey ,  Tianfeng Xu

IPC: A61K31/397 ,  C07D401/14 ,  C07D401/06 ,  C07D413/14 ,  C07D401/12 ,  C07D205/04 ,  A61K31/4523 ,  A61K31/4709 ,  A61K31/454 ,  A61K31/5377

Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US11168082B2

公开(公告)日：2021-11-09

申请号：US16611238

申请日：2018-05-15

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Dengyou Zhang ,  Canhui Zheng ,  Zhuo Chen ,  Liu Liu ,  Liyue Huang ,  Chao-Yie Yang

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.

公开(公告)号：US20200157091A1

公开(公告)日：2020-05-21

申请号：US16611238

申请日：2018-05-15

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Dengyou Zhang ,  Canhui Zheng ,  Zhuo Chen ,  Liu Liu ,  Liyue Huang ,  Chao-Yie Yang

IPC: C07D471/04 ,  C07D519/00

Abstract: The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.

公开(公告)号：US20190152947A1

公开(公告)日：2019-05-23

申请号：US16098147

申请日：2017-05-02

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Ke Zheng ,  Shilin Xu ,  Tianfeng Xu ,  Denzil Bernard ,  Liyue Huang

IPC: C07D401/14 ,  A61P35/00 ,  C07D401/04 ,  C07D405/04 ,  C07D211/34

Abstract: The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US20210198237A1

公开(公告)日：2021-07-01

申请号：US17101323

申请日：2020-11-23

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Ke Zheng ,  Shilin Xu ,  Tianfeng Xu ,  Denzil Bernard ,  Liyue Huang

IPC: C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D211/34 ,  A61P35/00

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.

公开(公告)号：US20210130401A1

公开(公告)日：2021-05-06

申请号：US16605057

申请日：2018-05-15

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Yangbing Li ,  Hacer Karatas ,  Liu Liu ,  Jeanne Stuckey ,  Yali Dou ,  Liyue Huang ,  Atsunori Kaneshige

IPC: C07K5/11 ,  A61K38/07 ,  A61K45/06

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, R4a, R4b, R5a and R5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.

公开(公告)号：US10899738B2

公开(公告)日：2021-01-26

申请号：US16098147

申请日：2017-05-02

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Shaomeng Wang ,  Angelo Aguilar ,  Ke Zheng ,  Shilin Xu ,  Tianfeng Xu ,  Denzil Bernard ,  Liyue Huang

IPC: C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D211/34 ,  A61P35/00

Abstract: The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.